Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC-BETS: Biomarker-driven treatment in mCRPC
NCT03385655Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2018
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of adavosertib, savolitinib, darolutamide, ocifisertib, ipatasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Canadian Cancer Trials Group. Started Aug 2018; status: active, not recruiting.
02
Drugs
adavosertibsavolitinibdarolutamideocifisertibipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03385655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385655.